Open-label Pilot Study of Ziprasidone for Refractory Generalized Anxiety Disorder

ArticleinJournal of Clinical Psychopharmacology 25(5):497-9 · November 2005with9 Reads
Impact Factor: 3.24 · DOI: 10.1097/01.jcp.0000177853.15910.de · Source: PubMed